Avondale Partners Upgrades Haemonetics (HAE) to Market Outperform
More News related to HAE
- Trading Review for Cerus Corp. Issued by Beacon Equity
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- Haemonetics Corp. (HAE) Posts Q2 EPS of $0.69, Tops by 4c
- Haemonetics Reports Double Digit Growth in Earnings for Second Quarter Fiscal 2010
- Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine
More News related to Upgrades
- Bank of America upgrades Weyerhaeuser (WY) to Buy
- FBR Capital Upgrades Bank of America (BAC) to Outperform After Capital Raise Announcement
- Boenning & Scattergood Downgrades NutriSystem (NTRI) to Neutral
- Raymond James Upgrades Newpark Resources (NR) to Outperform
- Raymond James Upgrades Culp (CFI) to Strong Buy
Avondale Partners upgrades Haemonetics (NYSE: HAE) from Market Perform to Market Outperform with a $72 price target.
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems and single use consumables for blood donors and surgical patients.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
